Recent reports demonstrate a hypocholesterolaemic effect of daily subcutaneous injections of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in different rat models of hyperlipidaemia. However, this effect is not seen after oral administration of HMG-CoA reductase inhibitors in rats. We found that oral administration of the HMG-CoA reductase inhibitor Simvastatin also had no effect on plasma cholesterol in severely hyperlipidaemic Nagase analbuminaemic rats (NAR). Simvastatin (an apolar compound dissolved in propylene glycol) was infused continuously for 28 days into the subcutis of control Sprague-Dawley rats (SDR) and NAR using an implanted osmotic pump. All doses which were effective in reducing cholesterol in the NAR (reductions up to -60070), reduced apolipoprotein AI but not apolipoprotein B and caused a severe inflammatory reaction in the dermis. Similar toxicity was observed in the SDR. Subcutaneous administration of the vehicle (propylene glycol) did not cause this reaction and did not affect plasma lipids. Administration of Lovastatin in osmotic pumps resulted in a similar inflammatory reaction. Incorporation of Simvastatin into liposomes did not diminish the toxic effect.
Summary
Recent reports demonstrate a hypocholesterolaemic effect of daily subcutaneous injections of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in different rat models of hyperlipidaemia. However, this effect is not seen after oral administration of HMG-CoA reductase inhibitors in rats. We found that oral administration of the HMG-CoA reductase inhibitor Simvastatin also had no effect on plasma cholesterol in severely hyperlipidaemic Nagase analbuminaemic rats (NAR). Simvastatin (an apolar compound dissolved in propylene glycol) was infused continuously for 28 days into the subcutis of control Sprague-Dawley rats (SDR) and NAR using an implanted osmotic pump. All doses which were effective in reducing cholesterol in the NAR (reductions up to -60070), reduced apolipoprotein AI but not apolipoprotein B and caused a severe inflammatory reaction in the dermis. Similar toxicity was observed in the SDR. Subcutaneous administration of the vehicle (propylene glycol) did not cause this reaction and did not affect plasma lipids. Administration of Lovastatin in osmotic pumps resulted in a similar inflammatory reaction. Incorporation of Simvastatin into liposomes did not diminish the toxic effect. On the other hand, infusion of Pravastatin (a polar HMG-CoA reductase inhibitor dissolved in isotonic saline) caused no changes in the dermis and had no effect on plasma lipids in NAR or SDR. Liver microsomes prepared from the Pravastatin-treated rats demonstrated a 3-to 4-fold increase in HMG-CoA reductase activity as compared to untreated rats, confirming uptake of the drug. We conclude that continuous subcutaneous administration of the HMG-CoA reductase inhibitors Simvastatin, Lovastatin and Pravastatin for 28 days may not reduce plasma cholesterol in rats by a mechanism which is related to inhibition of HMG-CoA reductase activity in the liver. The decrease of plasma cholesterol effected by subcutaneous infusion of Simvastatin or Lovastatin in NAR coincides with, and may be related to inflammatory changes caused by administering these compounds into the dermis.
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Liposomes; 3-Hydroxy-3methylglutaryl-CoA reductase Hypercholesterolaemia has been implicated to play a pathogenic role in chronic progressive renal disease (Moorhead et al., 1982) . Recently, inhibition of the rate controlling enzyme of cholesterol synthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMO CoA) reductase, has proved to be a very effective treatment in patients with secondary hyperlipidaemia due to the nephrotic syndrome (Rabelink et al., 1988) and preliminary observations indicate that this hypolipidaemic effect may result in amelioration of the disease (Rabelink et al., 1990) . Therefore it would be of interest to study the long-term effects of these lipid-lowering agents in an animal model. The Nagase analburninaernic rat (NAR; Nagase et al., 1979) , a mutant Sprague-Dawley rat (SDR), is severely hypercholesterolaemic (Ando et al., 1980; Joles et al., 1991) . This is probably a secondary hyperlipidaemia because albumin infusions lower serum lipid concentrations (Takahashi et al., 1983) . This has also been found in patients with hypoalbuminaemia due to the nephrotic syndrome (Baxter et 01., 1961) . Therefore the NAR may be a suitable model of secondary hyperlipidaemia for the study of longterm effects of HMG-CoA reductase inhibition.
In the above-mentioned clinical studies the HMG-CoA reductase inhibitor, Simvastatin, was administered orally (Rabelink et al., 1988; . Unfortunately, oral administration of HMG-CoA reductase inhibitors in normal (Bndo et al., 1979; Tsujita et al., 1986) rats has no substantial effect on blood cholesterol levels. However, in 5/6 nephrectomized Sprague-Dawley rats, a rat model of chronic renal failure and secondary hyperlipidaemia, daily subcutaneous injection of an analogous HMG-CoA reductase inhibitor, Lovastatin, reduced hypercholesterolaemia and also depressed glomerular injury and proteinuria (Kasiske et al., 1988a) . Similar effects were observed in obese Zucker rats (Kasiske et al., 1988b) and in rats with experimental nephrosis (Harris et al., 1990) after subcutaneous Lovastatin injection. In all three latter studies, Lovastatin, an apolar lactone compound which is poorly soluble in water, was dissolved in propylene glycol at a dose of 4 mg/kg body weight/day.
In this study we searched for a simple, effective method to reduce plasma cholesterol by the administration of the HMG-CoA reductase inhibitors Simvastatin and Lovastatin, both apolar lactone compounds of which Simvastatin is the more potent (Illingworth & Bacon, 1987) , Joles et al. and Pravastatin, a water-soluble polar acidic compound (Tsujita et al., 1986) with a potency equal to Lovastatin (Illingworth & Bacon, 1987) , chronically in the subcutis of NAR and SDR.
Materials and methods Animals A total of 69 adult (3-6 months old) female NAR from our own colony (founded with animals generously donated by Dr S Nagase, Tokyo, Japan) and 33 adult (3-6 months old) female SDR from a local supplier (Harlan-CPB, Zeist, The Netherlands) were used in 6 consecutive experiments. Female animals were used, as the female NAR is more severely hyperlipidaemic than the male NAR (Joles et 01., 1991) . The animals weighed about 300 g, and were maintained 3 to a Macrolon-3 cage under conventional conditions (tap water ad libitum, sawdust bedding, light: 0600-1800 h, temperature: 19-22°C, relative humidity: 45-55070)on a semisynthetic diet (Hope Farms, Woerden, The Netherlands) containing 20070 casein-protein, 10070corn starch, 50/0 cellulose, 53 glucose monohydrate, and 5% soybean oil (by weight). The remaining 7% consisted of salts, vitamins, and trace elements. Blood was sampled in the non-fasted state at the end of each trial by puncture of the abdominal aorta under fentanyldiazepam anaesthesia. The study was approved by the Utrecht University Medical Faculty Board for study in experimental animals.
Protocol
Six experiments were performed. Experiments 2-6 were set up consecutively and were all aimed at achieving reductions in plasma cholesterol without concommitant subcutaneous inflammation (see Results).
In the first experiment Simvastatin, dissolved in propylene glycol, was injected at a dose of 4 mg/kg body weight/day in the subcutis of the flank of 3 NAR for 28 days, daily for the first 2 weeks and 3 times per week in the last 2 weeks. Other animals received Simvastatin orally as a food-additive at a dose of 100 mg/kg food in a pelleted (4 NAR and 2 SDR) or a powder form (4 NAR and 2 SDR). Powdered diet was included because compressing the powder into pellets generates heat which might degrade the drug. The food was fed ad libitum. 4 NAR and 2 SDR were fed unmedicated pellets ad libitum.
In the second experiment osmotic pumps (Alzet®, model 2ML4; volume -2 m1)containing Simvastatin dissolved in propylene glycol at concentrations ranging from 0'25 to 4'Omg/ml, corresponding with 5 dose levels ranging from O'06 to 1.0 mg/kg! day, were implanted under aseptic conditions and fentanyl-diazepam anaesthesia in the subcutis of 18 NAR (3 at each dose). SDR (n = 6) were studied at 2 dose levels (0'5 and l'Omg!kg/day; 3 at each dose). Six SDR and 5 NAR received a pump with propylene glycol only. These pumps, which were also used in all the following experiments, administer their contents at a constant rate over a period of 28 days (Alzet Corp., Palo Alto, CA, USA).
In the third experiment osmotic pumps containing Lovastatin dissolved in propylene glycol at a concentration of 4, 0 mg/ml, corresponding to a dose of 1.0 mg/kg/ day, were implanted in the subcutis of 6 NAR and 6 SDR.
Because Simvastatin dissolved in propylene glycol at a cholesterol-lowering dose in NAR consistently caused cystic reaction around the pump, we attempted to incorporate Simvastatin into liposomes. Liposomes are suitable carriers for lipophilic, poorly water-soluble substances (Crommelin & Storm, 1990 )such as Simvastatin, and we hoped that they would transverse the subcutis with little local release of the drug.
In the fourth experiment Simvastatin, at a concentration of 1· 5 mg/ml was incorporated into liposomes. The Iiposomes were prepared by dissolving soybean phosphatidylcholine (PC, 120 mM) and egg yolk L-a-phosphatidyl-Lglycerol lPG, 24 mM both kindly donated by Natterman Chemie GmbH, Cologne, Germany] at a molar ratio of 10/2 and Simvastatin in chloroform; the chloroform was removed by roto-evaporation under vacuum forming a film on the glass wall. This film was redispersed with the aid of glass beads in an isotonic buffer solution consisting of 10mM Hepes and 0,138 mM NaCI 271 at pH 7, 4 (van Bloois et al., 1987) . All chemicals were of reagent grade. The Iiposomes were sonicated at a frequency of 55 kHz under N 2 at room temperature in an ultrasonic bath (Branson Ultrasonics Corp., Danbury, CT, USA) during 1 h, and passed through a sterile 200 nm filter (Nuclepore Corp., Pleasanton, CA, USA). The average particle size after filtration, determined by dynamic light scattering (Malvern, Worcestershire, UK), was 70 nm with a polydispersity (pd) of 0,47. Liposomes without Simvastatin ('empty' liposomes) were prepared similarly and had a particle size of 84 nm with a pd of 0,46. Solubilization of Simvastatin by liposomes was determined with a PU 8600 spectrophotometer (Pye Unicam Ltd, Cambridge, UK). Simvastatin dissolved in absolute ethanol showed an absorption maximum at 230 nm. Simvastatin in the Iipo somes was determined by dissolving the aqueous dispersion in ethanol; the calibration solutions contained apart from increasing Simvastatin concentrations a fixed concentration of Iiposomallipids. This determination indicated that 870/0of the starting amount of Simvastatin was incorporated into the liposomes. The Iiposomes were then further diluted with isotonic Hepes buffer to a Simvastatin concentration of I mg/ml realizing an infused dose of 0·25 mg/kg/day. Empty liposomes were diluted to exactly the same extent. Pumps with Simvastatin-containing Iiposomes were implanted in 5 NAR, and pumps with 'empty' liposomes in 3 NAR. No rats of the SDR strain were included in this or in the next experiment.
In the fifth experiment Simvastatin, at a similar concentration as in experiment 4, was incorporated into Iiposomes consisting of dialmitoylphosphatidylcholine (DPPC), dipalmitoyl phosphatidyl-glycerol (DPPG) and L-atocopherol (vitamin E) at a molar ratio of 10/2/5 in a similar buffer solution. These liposomes were sonicated at a frequency of 55 kHz, under N2 at 40-50°C and subsequently filtered. The average particle size was 92 nm with a pd of O'25. Similarly prepared 'empty' liposomes had a particle size of 76 nm with a pd of O' 30. were diluted to the same final concentration as in the previous experiment. Pumps with these Simvastatin-containing Iiposomes were also implanted in 5 NAR, and pumps with 'empty' liposomes in 3 NAR.
In the sixth experiment Pravastatin was dissolved in an isotonic NaCl solution (150 mmolll) at a concentration of 35 mg/ml realising a dose of 7, 5 mg/kg/ day. Pravastatin was administered with osmotic pumps to 6 SDR and 6 NAR. HMG-CoA reductase activity was determined in microsomal preparations from the livers of 2 SDR and 3 NAR. The activity of this enzyme was also determined in preparations from 6 untreated animals (3 SDR and 3 NAR).
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by routine microbiological screening and subcutaneous tissue adjacent to the pumps administering propylene glycol with or without Simvastatin was dissected and fixed in 4% (w/v) formaldehyde in O· 067 moll I Sorensen buffer (pH 6'9). The fixed material was embedded in paraplast according to conventional procedures and 5 Jtm sections were prepared at different levels of the tissue. The sections were stained with haematoxylin and eosin (H&E).
Statistical analyses
Values were subjected to one way analysis of variance (factored for dose) and a least significance test (comparing means of treated group to the mean of the control group). Results are presented as mean ± standard deviation. 
Experiment 1
Oral administration of Simvastatin over a period of 4 weeks in pelleted or powder chow caused no decrease in plasma cholesterol concentrations when compared to the levels found in the unmedicated control NAR or in the SDR (Table 1) .
Triglyceride levels were decreased significantly in the NAR (P<O'05), but not in the SDR.
Analyses
Enzymatic methods were used for the determination of plasma cholesterol (Boehringer, Mannheim, Germany). Plasma apolipoprotein (apo) AI was measured by electroimmunoassay (Dallinga-Thie et al., 1985) . Plasma apo B was measured by radial immunodiffusion as described (Staels et al., 1990) , using a specific antiserum raised in rabbits against purified rat low density lipoprotein (Van't Hooft & van Tol, 1985) .
Plasma apo B concentrations, expressed in arbitrary units (AU), were calculated as a percentage of a rat serum standard pool (obtained from 50 rats) run simultaneously on the plates with the plasma samples. The data are expressed in AU because of the insolubility of purified apo B and the lack of sufficient quantities of pure apoB for use as an absolute standard.
The HMG-CoA reductase activity in liver microsomes was determined essentially as described by Shapiro et al. (1974) . GroupO 
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Histopathology and microbiology
In the second experiment we observed considerable fluid accumulation around the Simvastatin-containing pumps (see Results). To study this phenomenon the fluid was examined°R ats received either control pelleted chow (pellet-O); powder chow to which Simvastatin (100 mg/kg) had been added (powder-S); pelleted chow to which Simvastatin (100 mg/kg) had been added (pellet-S); or subcutaneous injections of propylene glycol to which Simvastatin (4 mg/kg BW) had been added (sc-S). Mean ± S.D.
3P<0·05 versus pellet-O; bp<O'OS versus pellet-So Pretreatment levels of cholesterol and triglyceride were 10'0± 1'8 mmol/l and 10· 3 ± 2·0 mmol/l, respectively, in the NAR (n = 12) and 2·9 ± O' 5 mmol/l and 1. 3 ± O' 4 mmol/l, respectively, in the SDR (n = 6).
Daily subcutaneous injections of Simvastatin in propylene glycol in NAR caused a considerable local swelling and seemed to be painful as the rats became very aggressive and lost weight. In the third and fourth week we reduced the frequency of injection to 3 per week. After 28 days plasma cholesterol was 5,8 ± O' 8 mmol/l and triglycerides were 2·7 ± O' 5 mmol/l, values significantly lower than those found in the other groups (P<0'05; Table 1 ).
Experiment 2
In this experiment we attempted to administer Simvastatin in a less painful and more practical manner. Osmotic pumps (5' 1 xl· 4 em), filled with propylene glycol only or Simvastatin dissolved in propylene glycol, were implanted under aseptic conditions in the subcutis of the dorsal thorax.
After 28 days of implantation, inspection and palpation of the pump implantation site of the rats treated with propylene glycol only revealed no tissue swelling or undulation (Fig. 1) . Body weight changes were variable in these adult females [NAR: 6±29g (n=6); SDR: 17±7g (n = 6)]. Removal of the pump, post-mortem, disclosed a dry cavity enclosed in a thin, fibrous capsule. Judged from the H&E-sections, this pocket appeared to consist of a cavity lined by a thin layer of histiocytes and fibroblasts which covered a film layer of connective tissue. Underneath this layer, a loose subcutis was situated which was rich in blood vessels (Fig. 2) . Simvastatin, when administered at a dose above 0'06 mg/kg/day, caused accumulation of a mucous-like fluid in the capsule which was accumulations of neutrophilic granulocytes. A thin loose layer of histiocytes covered a chronic inflammatory reaction comprised of granulation tissue (Fig. 3) . The chronic part of the inflammation was interspersed by an acute component consisting of neutrophilic granulocytes. At some tissue levels, secondary necrosis, bordered by a demarcation zone of neutrophilic granulocytes, was also seen. Pretreatment levels of cholesterol and triglyceride were 8, 0 ± 2· 3 mmol/I and 5, 7 ± 2'4mmol/l, respectively, in the NAR (n=23) and 2'9± 0'3 mmol/I and 0'7 ± 0,3 mmol/I in the SDR (n = 12). Plasma cholesterol tended to formed around the osmotic pump in both NAR and SDR (indicated in Figs 4 and 5 as 'cyst').
In some cases this fluid was haemorrhagic, but routine microbiology revealed no microorganisms in any fluid sample. Light microscopic inspection showed that the sediment consisted of erythrocytes and leukocytes. It was difficult to assess the exact volume in the cyst but the changes in body weight [NAR: 57 ± 17 g (n = 15); SDR: 32 ± 15g (n = 6)] show that in some cases the volume must have exceeded 50 ml, causing extensive swelling (Fig. 1) No effect was seen in SOR on apo Al (Fig. 5A ), but apo B increased (P<0'05) during Simvastatin administration (Fig. 58 ). 
Experiment 4
Pretreatment levels of cholesterol and triglyceride were 7'6±0'9mmolll and 7'0±2'1 mmol/I, respectively, in the NAR (n=8). No rats of the SOR strain were included in this or in the next experiment. 'Empty' liposomes caused no cyst
Experiment 3
Lovastatin administration in the subcutis at a dose of 1·0 mg/kg/day caused cyst formation in 4 rats (1 NAR and 3 SDR). In the other rats (n = 7) the cap and flange which surround the outlet of the pump were enclosed in a firm capsule whereas the distal part of the pump containing the reservoir was separated from the surrounding tissue by a very thin flexible membrane. Histopathological inspection revealed inflammatory changes, resembling those seen after Simvastatin treatment, in all animals. One NAR, that died 2 weeks after the pump had been implanted, was excluded from the experiment. Pretreatment levels of cholesterol and triglyceride were 8'7±2'2mmolll and 8'0±4'4mmol/l, respectively, in the NAR (n = 5) and 2·7 ± 0,4 mmolll and I' 5 ± O' 5 mmolll in the SOR (n = 6). Plasma lipid levels (as compared to values found in vehicle-treated animals in the previous experiment) were low in 2 of the 5 NAR (cholesterol: 6, 2 and 6, 3 mmolll; triglyceride: 3' 2 and 3' 6 mmolll), one of which demonstrated a cyst. In the other 3 NAR normal plasma levels of cholesterol (79 ± 2' 0 mmolll) and triglycerides (7' 5 ± 1.2 mmol/I) were observed. In the SDR plasma cholesterol (2' 6 ± O·3 mmol/l) was not affected and triglyceride (0' 76 ± O' 3 mmol/I) was slightly decreased by Lovastatin. Apo Al concentrations after Lovastatin were 105± 42 mg/ IOOml in the NAR and 34±9mg/IOOml in the SOR, and apo B concentrations were 197± 13 AU in the NAR and 99± 55 AU in the SOR. The levels in the NAR are similar to those found after treatment with Simvastatin at a dose of 0-06mg/kg/day (Fig. 5) . decrease with increasing doses of Simvastatin in the NAR, reaching a maximum decrease of -500/0at 0-75 and 1·0 mg/kg/day (Fig. 4A) . Plasma triglycerides decreased even more, the maximum decrease (-80%) already being attained at a dose of 0·25 mg/kg/day. Plasma triglycerides also decreased by -50% at a dose of O'06 mg/kg/ day, a dose at which neither cyst formation, nor decreases in plasma cholesterol were observed (Fig. 4B) . Plasma apo Al decreased in a dose dependent fashion (P<0'05; Fig. SA ) but plasma apo B was not affected by Simvastatin treatment in the NAR (Fig. 58) . In the SOR no decrease in cholesterol (Fig. 4A ) and a slight decrease in triglycerides (Fig. 4B ) was observed. Table 2 . Plasma cholesterol (CH), plasma triglycerides (TG) and change in body weight (BW) in female Nagase analbuminemic rats (NAR) after 28 days of the administration of Simvastatin (Simva) in two types of liposomes (fourth and fifth experiment; see text). Simvastatin was incorporated into liposomes composed of soya bean phosphatidylcholine and egg yolk phosphatidylglycerol (molar ratio = 10 : 2) or into E-liposomes composed of dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidyl glycerol (DPPG) and vitamin E (a-tocopherol) at a molar ratio of 10/2/5. Both types of liposomes were infused subcutaneously using an osmotic pump (Alzet®, 2ML4) at a dose of 0'3 mg/kg/day. Unmedicated liposomes were also infused. Rats were fed control pelleted chow. Mean ± S.D. NAR Simva in liposomes 0 3 9·3± 1·7 5'2±2'4 0/3 -5± 4 NAR Simva in liposomes 0,3 5 5 '9± 0,7" 2· 7 ± 1· 3" 5/5 +46± 13 NAR
Simva in E liposomes 0 3 6'6± 0,4" 2·1 ±0'5" 3/3 -2±23 NAR
Simva in E liposomes 0,3 5 5' 3 ± I '7' 2' 7 ± 1,6' 5/5 + 13±20
'p<o·os versus dose 0 of the ordinary liposomes.
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formation (Table 2) . Cholesterol and triglyceride levels were similar to pretreatment levels and to those observed in the vehicle-treated group in Experiment 2. However, Simvastatin-containing liposomes consistently caused cyst formation. The cysts were macroscopically similar to those observed in the Experiment 2 with Simvastatin in propylene glycol. Plasma cholesterol and triglycerides were all consistently decreased.
Experiment 5
The liposomes used in the Experiment 4 were apparently not able to prevent the Simvastatininduced cyst formation in the subcutis. Thus in this experiment we modified the liposome composition. Liposomes were produced with DPPC, DPPG and vitamin E and were termed E-liposomes. The use of DPPC and DPPG in liposomes reputedly increases the in vivo stability as compared to the type used in the Experiment 4 (Crommelin & Storm, 1990) . Pretreatment levels of cholesterol and triglyceride were 10·2 ± 1.4 mmol/l and 10· 1± 3, 6 mmol/l, respectively, in the NAR (n = 8).
In this experiment Simvastatin-containing Eliposomes caused cyst formation, and a decrease in plasma cholesterol and triglyceride levels as compared to the levels found in animals treated with 'empty' liposomes in Experiment 4 (Table 2) . However, 'empty' E-liposomes also caused cyst formation, which was similarly accompanied by a decrease in plasma lipids.
Experiment 6
In the previous experiments plasma cholesterol only decreased when toxic effects were observed in the subcutis. In this experiment we administered another HMG-CoA reductase inhibitor, Pravastatin, that has no inhibitory action on sterol synthesis in the rat skin when administered orally (Tsujita et al., 1986) . This compound is soluble in water.
A high dose of this compound (7' 5 mg/kg BW/day) when administered into the subcutis with an osmotic pump for 28 days caused no inflammation or cyst formation in either NAR or SDR (Table 3) . Plasma lipid concentrations were not affected by administration of the drug. Apo Al concentration was 103± 38 mg/l00 ml in the NAR and 31 ± 4 mg/100 ml in the SDR, and apo B concentration was 145± 30 AU in the NAR and 87 ± 11AU in the SDR, values similar to those observed in the rats treated with propylene glycol only (Fig. 5) . Previously we had observed a similar absence of any effects in rats treated with lower doses of Pravastatin . Thus to confirm uptake of the drug we measured HMG-CoA reductase activity in liver microsomes isolated from these animals. HMG-CoA reductase activity in liver microsomes was not very different between the two Table 3 . Plasma cholesterol (CH), triglycerides (TG) and change in body weight (BW) in female Nagase analbuminemic rats (NAR) and control Sprague-Dawley rats (SDR) before (DO)and after 28 days (028) of Pravastatin administration. Pravastatin was dissolved in NaCI solution (150 mmol/l) at a dose of 7, 5 mg/kg BW/day and infused subcutaneously using an osmotic pump (Alzet@,2ML4).
Rats HMo-eoA reductase activity n (nmo//min/mg microsomal protein) 3 0'148±0'008 3 0-134 ± 0,048 2 0·629 ± O' 206 3 0'429 ± 0·110 strains (Table 4 ). Pravastatin administration induced a 3-to 4-fold increase in enzyme activity in both strains (P<0·05). Such increases have also been observed in rats treated orally with Compactin (Endo et al., 1979) and Lovastatin (Singer et af., 1984) .
Discussion
In patients with hypercholesterolaemia daily oral administration of HMG-CoA reductase inhibitors has a sustained depressive effect on blood cholesterol levels (Grundy, 1988) . In normal rats, however, this is not the case (Endo et af., 1979) . One exception is the obese Zucker rat (McCune & Jurin, 1987) . In this study oral administration. of Simvastatin in NAR also caused no change in plasma cholesterol levels. Plasma triglyceride levels, however, decreased by -35070. Similar reductions in plasma triglycerides found in. Wistar rats after 14 days of treatment with 0,4% Pravastatin in the drinking water (Yoshino et al. , 1988; Hirano et al., 1990) , and after 7 days of treatment with O' 1% Mevastatin in the diet (Endo et al., 1979) . The latter is 10 times the dietary concentration of Simvastatin used in the present study. This could be the reason why no change in plasma triglycerides was found in the SDR, although the molar activity of Mevastatin is somewhat lower than that of Simvastatin.
The major finding of this study is that subcutaneous administration of certain HMG-CoA reductase inhibitors to rats is associated with a local inflammatory response. Subcutaneous Simvastatin administration using osmotic pumps at a dose of O' 12mg/kg/ day and above caused the formation of a cavity filIed with mucous fluid lined with inflammatory tissue. This was also found in rats similarly treated with Lovastatin at a' dose of 1· 0 mg/kg/ day. AIl NAR treated with Simvastatin at a dose of O' 12mg/kg/ day and above showed decreases in plasma cholesterol in conjunction with the forementioned inflammatory reactions. The decrease in apo Al and the practically unchanged levels of apo B indicate that this decrease is caused by a decrease in high density lipoprotein, as apo Al is mainly located on these particles (Dallinga-Thie et al., 1985) . This reduction is in direct contrast with the reaction to Simvastatin in 'humans with secondary hyperlipidaemia due to the nephrotic syndrome (Rabelink et at., 1988) where there is an increase in high-density lipoprotein cholesterol and apo Al and a decrease in low density lipoprotein and apo B. Thus the changes in circulating apolipoproteins induced by subcutaneous Simvastatin and Lovastatin treatment in the NAR are very different from those seen in hyperlipidaemic humans. Lovastatin seemed to be less toxic in the subcutis than Simvastatin, and the effect on plasma lipids in the NAR was also more variable.
In humans Simvastatin has been reported to be -30070 more potent than Lovastatin as a cholesterol reducing agent (Illingworth & Bacon, 1987) . Comparison of the changes in apo Al levelsafter Lovastatin at a dose of 1·0 mg/kg/day reveal a decrease which is comparable to that found at a dose of Simvastatin equal to 0,06 mg/kg/day. This may explain why in other studies, where Lovastatin was injected into the subcutis of rats at the same dose (4 mg/kg BW/day) daily for 60 days (Harris et at., 1990) , 70 days (Kasiske et al., ]988a) or 224 days (Kasiske et at., 1988b) , no toxic effects were reported. Plasma apo levels were not reported in the latter studies.
Incorporation of Simvastatin into PC/PO liposomes did not prevent the occurrence of subcutaneous toxicity. Upon intravenous injection the selected small liposomes consisting of PC/PO are considered to be able to release the encapsulated drug rapidly in blood plasma via exchange processes or by complete disintegration of the liposomal structure (Crommelin & Storm, 1990) . Under the present conditions (release in the subcutis) no definite conclusions can be drawn concerning the site of Simvastatin release. However, one can speculate that these particles release Simvastatin in the subcutis as they are too instable to leave the subcutis without being degraded. Liposomes consisting of DPPC-DPPO are supposedly more stable than the earlier used PC/PO type (Crommelin & Storm, 1990) . Vitamin E (L-Cl!-tocopherol)was added to the DPPC·DPPO liposomes to protect against peroxidation reactions which may be involved in the cyst formation process. However, Joles et al. DPPC-DPPG-vitamin E liposomes manifested an unexpected intrinsic irritative effect in the rat subcutis. This observation suggests that chronic subcutaneous administration of hydrophobic, lipophilic substances causes local irritation, and that the primary inflammatory changes observed in the subcutis were not related to an inhibition of cellular cholesterol synthesis. As was the case for Simvastatin in propylene glycol, every time that we encountered these toxic effects in the subcutis of the NAR, we also found decreases in plasma cholesterol and triglycerides. This was even the case after implantation of unmedicated liposomes assembled from DPPC-DPPG-vitamin E. The reason for the toxicity of 'empty' DPPC-DPPG-vitamin E liposomes is not known. Possibly their increased stability as compared to PC/PG liposomes causes them to reside in the subcutis for a longer period of time, thus causing more local inflammation. No further efforts were made to clarify this issue.
The lactone group of the water-insoluble compounds Simvastatin and Lovastatin is enzymatically hydrolyzed to the corresponding dihydroxycarboxylate (Alberts, ]988). The readily water-soluble Pravastatin is an open acid analogue of Lovastatin; additionally at the 6Cl! position the methyl group has been substituted by a hydroxyl group (Tsujita et at., 1986) . Which of these two differences in chemical structure is responsible for the difference in inflammatory reaction in the subcutis is unknown. Topical Lovastatin administration on the skin of hairless mice caused a marked reduction in cholesterol synthesis in epidermis and dermis (Feingold et at., 1990) . Possibly the differences between Pravastatin on the one hand and Lovastatin and Simvastatin on the other hand are due to the higher polarity of Pravastatin which hinders uptake into intact non-hepatic cells. Interestingly, cholesterol synthesis in intact lenses of rats and rabbits was inhibited 100-fold less by Pravastatin as compared to Lovastatin and Simvastatin, whereas in broken lens cell preparations Pravastatin and Lovastatin were equally effective inhibitors of HMO-CoA reductase (Mosley et at., ]989). The higher polarity of Pravastatin may also explain the absence of toxic effects observed in our study. Alternatively, the inflammatory effect of a hydrophobic, lipophilic solvent such as propylene glycol in the subcutis may be aggravated by a cholesterol synthesis inhibitor. Topical treatment with Lovastatin also impaired the recovery of the barrier function of the skin after disruption with acetone (Feingold et al., 1990) .
Combining all the data leads us to the conclusion that the continuous subcutaneous administration of Simvastatin, Lovastatin or Pravastatin for 28 days does not reduce plasma cholesterol in NAR by a mechanism related to HMG-CoA reductase inhibition. The decrease of cholesterol effected by subcutaneous infusion of Simvastatin, Lovastatin and by liposomes consisting of DPPC/DPPG/vitamin E (without or with Simvastatin) may be related, directly or indirectly, to the inflammatory changes in the dermis.
